Exhibit 10.29
[***] Confidential treatment requested
CONTRACT MANUFACTURING AGREEMENT
This CONTRACT MANUFACTURING AGREEMENT (the "Agreement") is entered into as of January 3,
2003 (the "Effective Date"), by and between ICOS Corporation ("ICOS"), a corporation organized and existing
under the laws of the State of Delaware and having its principal place of business at 22021 20/th/ Avenue S E,
Bothell, WA 98021 USA and Seattle Genetics, Inc. ("SGI"), a corporation organized and existing under the laws
of the State of Delaware and having its principal place of business at 21823 30th Drive S.E., Bothell, WA
98021.
RECITALS
WHEREAS, ICOS is in the business of manufacturing and testing pharmaceutical products; and
WHEREAS, SGI is the proprietor of a certain DNA known as SGN-30 encoding a monoclonal antibody also
known as SGN-30; and
WHEREAS, ICOS has expertise in the development, evaluation and production of monoclonal antibodies for
therapeutic use using cell lines; and
WHEREAS, subject to the terms and conditions set forth in this Agreement, SGI wishes to have ICOS
manufacture for SGI a pre-commercial pharmaceutical Product (hereinafter defined); and
WHEREAS, subject to the terms and conditions set forth in this Agreement, ICOS wishes to manufacture
Product for SGI.
NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows:
1. Definitions
For purposes of this Agreement, the following terms will have the meanings set forth below:
1.1 "Affiliates" means, with respect to any Person, another Person that, directly or indirectly, controls, is
controlled by or is under common control with such Person. The term "control" means the possession, directly or
indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether
through the ownership of voting securities, by contract or otherwise. The direct or indirect ownership of at least
fifty percent (50%) or, if smaller, the maximum allowed by applicable law, of the